Ken Griffin
SABS icon

Ken Griffin’s SAB Biotherapeutics SABS Stock Holding History

Ken Griffin’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,650
Closed -$70.4K – 14079
2025
Q4 		$66K Buy
+17,650
New +$58.1K ﹤0.01% 11899
2025
Q3 		– Sell
-17,095
Closed -$29.9K – 13924
2025
Q2 		$29.9K Buy
+17,095
New +$28.3K ﹤0.01% 11977
2024
Q4 		– Sell
-10,305
Closed -$27.8K – 15261
2024
Q3 		$27.8K Buy
+10,305
New +$28.5K ﹤0.01% 12502
2024
Q1 		– Sell
-1,672
Closed -$11.5K – 15347
2023
Q4 		$11.5K Buy
+1,672
New +$14K ﹤0.01% 13043
2023
Q2 		– Sell
-2,840
Closed -$12.5K – 15105
2023
Q1 		$12.5K Sell
2,840
-8,082
-74% -$51.1K ﹤0.01% 13407
2022
Q4 		$64.4K Buy
10,922
+6,906
+172% +$63.1K ﹤0.01% 11815
2022
Q3 		$28K Buy
+4,016
New +$39.9K ﹤0.01% 11941
2022
Q1 		– Sell
-2,423
Closed -$189K – 14450
2021
Q4 		$189K Sell
2,423
-765
-24% -$71.8K ﹤0.01% 11930
2021
Q3 		$321K Sell
3,188
-642
-17% -$64K ﹤0.01% 10916
2021
Q2 		$382K Sell
3,830
-777
-17% -$77.1K ﹤0.01% 10680
2021
Q1 		$452K Buy
+4,607
New +$461K ﹤0.01% 9897

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ken Griffin's SABS Position: Q1 2026 in Review

Ken Griffin sold out of SAB Biotherapeutics (SABS) in Q1 2026, closing a stake of 17,650 shares — an estimated $70.4K sold.

Ken Griffin first reported a position in SABS in Q1 2021 and held it in 11 quarters. The position peaked at $452K in Q1 2021. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Ken Griffin reported no remaining SAB Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 17,650 SAB Biotherapeutics shares in Q1 2026, an estimated $70.4K.
  • Ken Griffin first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 11 quarters.
  • Ken Griffin's SAB Biotherapeutics position peaked at $452K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.